Scientific Program Day One

Tuesday | October 17, 2023

7:00 am Morning Coffee & Registration

8:15 am Chairperson’s Opening Remarks

  • Robert Lutz Chief Scientific Officer, Iksuda Therapeutics

Illustrating Cutting-Edge Antibody-Drug Conjugates Revolutionizing the Oncology Field

8:30 am Outlining the Phase III Approval of ImmunoGen’s ELAHERE, Lessons Learned & Next Steps


  • Exploring the rollercoaster journey of ImmunoGen’s Mirvetuximab Soravtansine, which targets folate receptor alpha
  • Emphasizing the importance of designing a clinical trial to enrol the right patients and utilizing biomarker strategies
  • Discussing the next steps for ImmunoGen following this ground-breaking approval

9:00 am Our History To Serve The Innovators: A Step Ahead Against The Challenges Of The Bioconjugates


  • Exploring a sustainable business model
  • Discussing expertise, technology and integration of services
  • Examining capacity shortage challenges: what it means going forward?

9:30 am Discussing the Role Daiichi Sankyo & AstraZeneca’s ENHERTU Has Played in Developing & Expanding the Antibody-Drug Conjugate Field

  • Gerold Meinhardt Vice President - Asset & Portfolio Management, Daiichi Sankyo, Inc.


  • The approval of Daiichi Sankyo & AstraZeneca’s ENHERTU for HER2-low breast cancer has continued to make major waves throughout the ADC field
  • Exploring the next steps in utilizing ADCs in breast cancer following this approval
  • Discussing the unique features of TOPO1-inhibitor that make ENHERTU so effective

10:00 am Morning Refreshments & Speed Networking


This session is the ideal opportunity to introduce yourself to the attendees that you would like to have more in-depth conversations with. Utilize this dedicated networking time for face-to-face interactions with many of the brightest minds working in the ADC field to form meaningful business relationships, and swap business cards using our app.

Track 1: Discovery Chemistry

Discovery Chemistry

Chair: Thomas Nittoli, Senior Director, Regeneron

Cutting-Edge Conjugation Technologies Spearheading the Early Discovery ADC Field

Download the Full Event Guide for full details

11.00 Novel Technologies for Expanding ADC Therapeutic Index

Shalom Goldberg, Senior Principal Scientist, Johnson & Johnson

11:30 Highly Selective ADCs With OHPAS-able & PMT-able Camptothecins: Basics of OHPAS Linker

Tae Kyo Park, Chief Executive Officer, IntoCell

12:00 Development of Next-Generation ADCs Using Novel Expression Platforms & Precise Conjugation

Gang Yin, Vice President Protein Chemistry, Sutro Biopharma

12:30 Maximizing Payload Potential Through Linker and Bioconjugation Technologies

Johanna Midelet, Bioconjugation Manager, Abzena

Track 2: Cellular Biology
Track 3: Translational
Track 4: Clinical Lessons
Track 5: Process & Analytical Development
Track 6: Manufacturing & Supply Chain

1:00 pm Lunch & Learn with Sterling Pharma Solutions

Track 1: Discovery Chemistry

Discovery Chemistry

Designing Your ADC to Minimize Off-Target Toxicities

Download the Full Event Guide for full details

2.00 Discovery of Novel Linker Payloads with Improved Efficacy & Therapeutic Index for Site-Specific ADCs

Krishna Bajjuri, Senior Director, Chemistry, Sutro Biopharma

2:30 Technological & Biochemical Innovations for Expanding the Therapeutics Index of ADCs

Christine Köhler, Head of Antibody Engineering, Veraxa Biotech

3:00 Towards Designing Ultra-Low Dose Precision Immunotherapeutics Without Toxicities

Jan Schnitzer, Founder, Director & Chief Executive Officer, PRISM

Track 2: Cellular Biology
Track 3: Translational
Track 4: Clinical Lessons
Track 5: Process & Analytical Development
Track 6: Manufacturing & Supply Chain

3:30 pm Technology Slam & Afternoon Networking Break


As you enjoy your afternoon refreshments, you will also have the chance to be face-to-face with the field’s most innovative and exciting technology providers. Join our dedicated technology slam to identify your next technology provider and progress your antibody-drug conjugate pipeline smoothly and efficiently.

Outlining Trailblazing Antibody-Drug Conjugate Clinical Candidates

4:30 pm Case Study: Exploring Novel Antibody-Drug Conjugates Storming Through the Clinic

  • Andreas Pahl Chief Scientific Officer & Member of the Executive Board, Heidelberg Pharma


  • Following a record-breaking year for ADCs entering the clinic, this session will focus on some of the most exciting clinical candidates and positive Phase I data
  • Discussing the key preclinical data indicative of future clinical success
  • Outlining different clinical trial designs, with the disadvantages and advantages of each design

5:00 pm Innovative Chitooligosaccharide-Based Solubility Enhancer for Linker-Payloads: Improved Efficacy & New Life for Challenging Payloads

  • Ross Bemowski Associate Director, API Research and Development, MilliporeSigma


  • Introduction to Chetosensar™ technology, a new chitooligosaccharide-based solubility enhancer that can be used with a wide range of linker-payload chemistries and conjugation methods
  • Discussion of in vitro studies demonstrating increased efficacy and previously unattainable high DAR species
  • Overview of how Chetosensar™ technology works with our CDMO services and ADCore™ intermediates to deliver rapid access to new linker-payloads 

5:30 pm Precision Engineering for Enhanced Therapeutic Index: Designing Antibody-Drug Conjugates (ADCs) for Broadened Efficacy & Safety

  • Alice Yam Executive Director, Preclinical Portfolio, Sutro Biopharma


  • Discovery and development if a novel Tissue Factor ADC with potent efficacy and strong safety using a newly designed linker payload
  • Exploration of linker-payload attributes that improve safety and widen the therapeutic index
  • Exploring what is on the horizon for next-generation ADCs? ADC2 modality combines synergistic payload mechanisms for targeted synthetic lethality

6:30 pm Poster Session & Drinks Reception


Join your peers in the ADC field by presenting your work in our dedicated ADC poster session. This is the perfect opportunity to discuss, debate, and display your work in the field, while enjoying a drink of your choice at our dedicated drinks reception.